Readmission penalties to double

The number of hospitals facing financial penalties for hospital readmissions deemed unnecessary within 30 days will remain steady next year but the punishment will double.

The Center for Medicare & Medicaid Services' (CMS) hospital readmissions reduction program is expected to cut Medicare spending on hospitals by about $227 million during the federal fiscal year starting Oct. 1, according to a 2,225-page final rule published Aug. 2. In this second round of the program, 18 hospitals will lose 2 percent, the maximum possible and double the current top penalty. Another 154 hospitals will lose 1 percent or more of every payment for a patient stay. Medicare is increasing penalties for a total of 1,074 hospitals and 283 hospitals not fined in the current year that will be penalized in the new round.

A federal data analysis shows about 2,200 hospitals will see reductions of up to 2 percent of their Medicare payments starting Oct. 1 under a program in the Patient Protection and Affordable Care Act that directed CMS to cut reimbursements to hospitals with high rates of readmissions. The penalties have been up to 1 percent of Medicare payments for the past year, and are scheduled to top out at 3 percent beginning in October 2014.

For 2012 and 2013, the penalties were based on statistics of patients readmitted to any Medicare hospital within 30 days following a stay for pneumonia, heart failure or heart attack. In October 2014, three more conditions will fall under the readmissions program: chronic obstructive pulmonary disease and arthroplasties of the total hip and total knee.

 

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.